Ga 700 Banner


The 3rd Theranostics World Congress (3TWC) took place on the campus of Johns Hopkins University on March 12-14, 2015.

We received over 100 abstracts for the World Congress.  Thank You!

This activity has been approved for AMA PRA Category 1 Credits

The Congress, Co-sponsored by the Society of Nuclear Medicine and Molecular Imaging (SNMMI) and Johns Hopkins Medicine, is intended for chemists, physicists, technologists, physicians and all scientists and clinicians interested in translational research and current state-of-the-art molecular imaging using 68Ga PET radiopharmaceuticals and radionuclide therapy. The increase in enthusiasm for 68Ga use over the last several years can be ascribed to several factors, some of which promise an increasing role for 68Ga as a tool in both diagnostic and therapeutic applications such as theranostics. The term "theranostics" symbolizes the inseparability of diagnosis and therapy and has a profound effect personalized disease management. Click here to download the Congress Flyer.

The radiopharmaceutical Gallium-68 (DOTA0-hel-Tyr3) octreotide (Ga-68 DOTATOC) has been designated as an orphan drug by the US Food and Drug Administration (FDA) for the management of neuroendocrine tumors. This designation is significant because it may lead to faster approval of the agent, which would greatly benefit carcinoid/NET patients in the United States. Click here to read the full release from the Society of Nuclear Medicine and Molecular Imaging.

A public meeting was held at the 2013 SNMMI annual meeting in Vancouver, Canada.  The following pdf was made available to those in attendance highlighting clinical trials at the University of Iowa and Vanderbilt University as well as general information on the Ga68 imaging and the challenges of bringing it to market in the US.